Clinical Report: Vyriad Begins First-in-Human Trial of In Vivo CAR T Therapy VV169
Overview
Vyriad has initiated a phase I trial of VV169, a novel in vivo CAR T therapy targeting BCMA for patients with relapsed or refractory multiple myeloma. This off-the-shelf lentiviral therapy generates CAR T cells directly within the body.
Background
The treatment landscape for relapsed or refractory multiple myeloma is evolving, with CAR T-cell therapies showing promise. Traditional autologous CAR T therapies require complex manufacturing processes that can delay treatment. VV169 does not require patient-derived T cells.
Data Highlights
The phase I trial will enroll up to 40 adults and assess safety, tolerability, and clinical activity of VV169.
Key Findings
VV169 is designed to generate BCMA-targeted CAR T cells in vivo.
The therapy is administered as a T-cell-targeted lentiviral vector via intravenous infusion.
Primary endpoints include adverse events, serious adverse events, and maximum tolerated dose.
The trial will evaluate the expansion and persistence of CAR T cells generated in vivo.
Participants will be followed for safety and tolerability for up to two years.
Clinical Implications
The VV169 trial will assess the feasibility of in vivo CAR T-cell generation.
Conclusion
The initiation of the VV169 trial marks a step in CAR T-cell therapy development.
